C19-9-21, a novel pan-αv integrin inhibitor with high binding affinity and efficacy in models of CRPC
July 17, 2023
Researchers from Peking University (PKU) recently presented the discovery and preclinical evaluation of a novel small-molecule inhibitor of pan-αv integrin, C19-9-21, being developed for the treatment of prostate cancer.
